Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Clinical trial NCT06138587 · RECRUITING

Trial details

NCT number: NCT06138587
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Leukemia Leukemia, Myeloid Myelodysplastic Syndromes Myeloproliferative Neoplasm Myeloproliferative Disorders

Start date: 2024-01-24
Primary completion: 2027-02-28
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.